Christopher Anzalone

Christopher Anzalone

President and Chief Executive OfficeratArrowhead Pharmaceuticals· In proxies 2021–2025

Pay in FY2025-27% from the year before · Arrowhead Pharmaceuticals stock +78.1% the same year

Christopher Anzalone was paid $9.0M in FY2025 (Sep), down 27%. Arrowhead Pharmaceuticals stock rose 78.1% that year.

Pay$100 in the stock at the end of FY20 → $80
Pay is from the Summary Compensation Table of each Arrowhead Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Arrowhead PharmaceuticalsPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role +35%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?